Harpoon Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Abstracts for HPN217 and HPN328 accepted for presentations at the International Myeloma Society (IMS) Annual Meeting and the European Society for Medical Oncology (ESMO) in the fall Enrollment for HPN328 (DLL3) ongoing;